Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
← catalyst calendarNCT07291323 · readout ≤ 73 d
Sponsored by Janux Therapeutics (industry) · JANX — their whole pipeline →.
Phase
Early Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-16 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Autoimmune
Intervention
- Drug: JANX011
Primary outcome
what the primary-completion date above is the date OFIncidence, severity, and relatedness of TEAEs, treatment-emergent SAEs, and treatment-emergent AESIs.
measured Up to 85 days
Permalink · JANX's whole pipeline · Catalyst calendar · Every registered study · What changed